Trial · NCT06698965
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The incidence of grade ≥ 3 neutropenia during chemotherapy treatment | From enrollment to the end of Cycle 6 (each cycle is 21 days) | According to CTCAE5.0 |
| Secondary | The incidence of ≥ grade 3 thrombocytopenia or anemia during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The duration of severe neutropenia in the first treatment cycle | From enrollment to the end of Cycle 1 (each cycle is 21 days) | |
| Secondary | The incidence of febrile neutropenia during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of granulocyte colony-stimulating factor (PEG-G-CSF/G-CSF) during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | Disease burden of patients during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | Based on EQ-5D-5L scales scores（The score range is from 5 to 25 points, with higher scores indicating better outcomes） |
| Secondary | The usage rate of erythropoietin (ESA) during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of recombinant human interleukin-11 during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of thrombopoietin (TPO) during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The usage rate of iron supplement during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The incidence of platelet transfusion during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | The incidence of red blood cell transfusion during chemotherapy | From enrollment to the end of Cycle 6 (each cycle is 21 days) | |
| Secondary | ORR | From enrollment to the end of Cycle 6 (each cycle is 21 days) | Objective response rate |
| Secondary | DCR | From enrollment to the end of Cycle 6 (each cycle is 21 days) | disease control rate |
| Secondary | DOR | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months | Duration of response |
| Secondary | PFS | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months | Progression-Free-Survival |
| Secondary | OS | From date of randomization until the date of death from any cause, assessed up to 60 months | Overall survival |
| Other | Dynamic changes of immune cell subsets and cytokines in peripheral blood before and after treatment | From enrollment to the end of Cycle 6 (each cycle is 21 days) | Including but not limited to the ratio of CD8+T/Treg and the number of T cell clones |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06698965/registered